Recent news on Oxsoralen-Ultra

Valeant Pharmaceuticals Reports Fourth Quarter and Full-Year 2006 ...  -  Feb 28, 2007
American Digital Networks (press release),10% Dermatology Efudix/ Efudex(P) 32295 14307 126% 78357 60179 30% Kinerase(P) 6431 6090 6% 28937 22267 30% Oxsoralen- Ultra(P) 2814 1820 55% 10528 9364

JSJ Pharmaceuticals Assumes Sales & Marketing Responsibility of ...  -  Feb 7, 2007
PR Newswire (press release),Oxsoralen-Ultra(R) is an important product for the treatment of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms

Valeant Pharmaceuticals Reports Preliminary 2006 Third Quarter ...  Nov 2, 2006
2006 Preliminary ----- Dermatology Efudix/Efudex(P) $ 15,502 Kinerase(P) 6,622 Dermatix(P) 2,553 Eldoquin(P) 1,935 Oxsoralen-Ultra(P) 613 ... -Genetic Engineering News (press release), Valeant Pharmaceuticals Reports 2006 Second Quarter Results ...  Aug 3, 2006
Dermatology Efudix/ Efudex(P) $14,978 $12,231 22% $30,560 $31,507 (3%) Kinerase(P) 9,024 5,821 55% 15,884 10,256 55% Oxsoralen- Ultra(P) 3,593 4,126 (13 ... -Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional